Wells Fargo’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Wells Fargo’s Portfolio MTCR Stock Details MTCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-241	Closed	-$108	–	7887
2022 Q4	$108	Buy	241 +6	+3%	+$2	﹤0.01%	6774
2022 Q3	$0	Buy	235 +42	+22%	+$21	﹤0.01%	7792
2022 Q2	$0	Buy	193 +17	+10%	+$8	﹤0.01%	7888
2022 Q1	$0	Buy	176 +96	+120%	+$50	﹤0.01%	8205
2021 Q4	$0	Buy	80 +1	+1%	+$2	﹤0.01%	8127
2021 Q3	$0	Sell	79 -685	-90%	-$2.14K	﹤0.01%	7793
2021 Q2	$3K	Sell	764 -1,303	-63%	-$5.39K	﹤0.01%	6499
2021 Q1	$13K	Sell	2,067 -1,393	-40%	-$12.3K	﹤0.01%	6277
2020 Q4	$27K	Buy	+3,460	New	+$31.7K	﹤0.01%	5784

Other funds holding MTCR

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Wells Fargo's MTCR Position: Q1 2023 in Review

Wells Fargo sold out of Metacrine, Inc. Common Stock (MTCR) in Q1 2023, closing a stake of 241 shares — an estimated $108 sold.

Wells Fargo first reported a position in MTCR in Q4 2020 and held it in 9 quarters. The position peaked at $27K in Q4 2020. 5 funds tracked by Wall St. Rank hold MTCR as of Q1 2023.

Wells Fargo reported no remaining Metacrine, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Wells Fargo sold 241 Metacrine, Inc. Common Stock shares in Q1 2023, an estimated $108.
Wells Fargo first reported a position in Metacrine, Inc. Common Stock in Q4 2020 and held it in 9 quarters.
Wells Fargo's Metacrine, Inc. Common Stock position peaked at $27K in Q4 2020.
5 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q1 2023.

Based on Wells Fargo's 13F filing for Q1 2023, filed 12 May 2023.